Author Archives: Forest Ray PhD

Inversago Raises $35M to Develop Therapies for PWS, Other Disorders

Inversago Pharma has obtained $35 million in financing to advance the development of therapies for disorders such as Prader-Willi syndrome (PWS). The investment will support studies of INV-101, the company’s lead compound, and other selected compounds for the treatment of metabolic and fibrotic (scarring) disorders. INV-101 is an…

Lowest Dose of LV-101 Fares Well in Phase 3 Trial of PWS Children

Children with Prader-Willi syndrome (PWS) experience significant reductions in their excessive hunger, anxiety and distress behaviors when treated with the lowest dose of Levo Therapeutics’ LV-101 (intranasal carbetocin) in a Phase 3 clinical trial, the company announced. While the highest dose under investigation (9.6 mg ) did…